Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant

Leukemia and Lymphoma

Volumn 53, Issue 8, 2012, Pages 1525-1529

  Beitinjaneh, Amer M ^a,b   Saliba, Rima ^a   Bashir, Qaiser ^a   Shah, Nina ^a   Parmar, Simrit ^a   Hosing, Chitara ^a   Popat, Uday ^a   Anderlini, Paolo ^a   Dinh, Yvonne ^a   Qureshi, Sofia ^a   Rondon, Gabriela ^a   Champlin, Richard E ^a   Giralt, Sergio A ^c   Qazilbash, Muzaffar H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

donor lymphocyte infusion; multiple myeloma; Stem cell transplant

Indexed keywords

CYCLOSPORIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADULT; ARTICLE; CD3+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL EVALUATION; DISEASE COURSE; DONOR LYMPHOCYTE INFUSION; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SAFETY; SURVIVAL; TOXICITY; TREATMENT RESPONSE;

ADULT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS TUMOR EFFECT; HUMANS; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; MULTIPLE MYELOMA; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84864196801     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.656635     Document Type: Article

References (28)

1. d e Lavallade H, El-Cheikh J, Faucher C, et al. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplant 2008;41:953-960.
2. B adros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001;97:2574-2579.
3. G arban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99 - 03 trial) with tandem autologous stem cell transplantation (IFM99 - 04 trial) in high-risk de novo multiple myeloma. Blood 2006;107:3474-3480.
4. B runo B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007;356:1110-1120.
5. R osinol L, Perez-Simon JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008;112:3591-3593.
6. L ahuerta JJ, Martinez-Lopez J, Serna JD, et al. Remission status defi ned by immunofi xation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000;109:438-446.
7. A yuk F, Shimoni A, Nagler A, et al. Effi cacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia 2004;18: 659-662.
8. L okhorst HM, Wu K, Verdonck LF, et al. Th e occurrence of graftversus- host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004;103: 4362-4364.
9. S alama M, Nevill T, Marcellus D, et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000;26:1179-1184.
10. v an de Donk NW, Kroger N, Hegenbart U, et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006;37:1135-1141.
11. Kroger N, Badbaran A, Lioznov M, et al. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol 2009;37:791-798.
12. Ayuk F, Shimoni A, Nagler A, et al. Effi cacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia 2004;18: 659-662.
13. Peggs K, Mackinnon S. Graft-versus-myeloma: are durable responses a clinical reality following donor lymphocyte infusion? Leukemia 2004;18:1541 - 1542; author reply 1542-1543.
14. Champlin R, Giralt S, Przepiorka D, et al. Selective depletion of CD8- positive T-lymphocytes for allogeneic bone marrow transplantation: engraftment, graft-versus-host disease and graft-versus leukemia. Prog Clin Biol Res 1992;377:385 - 394; discussion 395-398.
15. Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk stratifi cation in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011;117:4696-4700.
16. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graftversus- host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-217.
17. Mohty M, Attal M, Marit G, et al. Th alidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myelome (IFM) and the Societe Francaise de Greff e de Moelle et Th erapie Cellulaire (SFGM-TC). Bone Marrow Transplant 2005;35:165-169.
18. D azzi F, Szydlo RM, Craddock C, et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000;95:67-71.
19. Peggs KS, Th omson K, Hart DP, et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004;103: 1548-1556.
20. Peggs KS, Mackinnon S, Williams CD, et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant doseescalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited effi cacy of graft-versus-tumor activity. Biol Blood Marrow Transplant 2003;9:257-265.
21. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995;86:1261-1268.
22. Kernan NA, Collins NH, Juliano L, et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 1986;68:770-773.
23. Miller JS, Weisdorf DJ, Burns LJ, et al. Lymphodepletion followed by donor lymphocyte infusion (DLI) causes signifi cantly more acute graft-versus-host disease than DLI alone. Blood 2007;110: 2761-2763.
24. Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995;86: 4337-4343.
25. B yrne JL, Fairbairn J, Davy B, et al. Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/ plasmacytoma despite ongoing molecular remission. Bone Marrow Transplant 2003;31:157-161.
26. C hong G, Byrnes G, Szer J, et al. Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy. Bone Marrow Transplant 2000;26:1011-1015.
27. Kumar S, Fonseca R, Dispenzieri A, et al. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood 2003;101: 1715-1717.
28. Tricot G, Vesole DH, Jagannath S, et al. Graft-versus-myeloma eff ect: proof of principle. Blood 1996;87:1196-1198.